GERMS
Tuesday, April 23, 2013
Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™ | Merck Newsroom Home
Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™ | Merck Newsroom Home
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
‹
›
Home
View web version
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.